The effect of activated protein C in the experimental disseminated intravascular coagulation model formed by lipopolysaccharide infusion

Öahin, Abdullah; Özer, Nazmi

doi:10.1590/acb351102

Cited by 1 publication

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DIC model was induced in rats by continuously infusing them with LPS (30 mg/kg, dissolved in 10 mL sterile saline; Escherichia coli 055: B5; Sigma-Aldrich, St. Louis, MO, USA) via the tail vein for up to 4 h [ 2 , 53 ]. The control group (sham) was injected with the same volume of saline.…”

Section: Methodsmentioning

confidence: 99%

“…Disseminated intravascular coagulation (DIC) is a clinical syndrome with high mortality caused by activation of systemic intravascular coagulation [ 1 ]. It usually develops as a critical complication in patients with life-threatening conditions, such as severe infection, severe sepsis, malignancies, severe trauma, placental abruption, and obstetric calamities [ 2 ]. In particular, in the last period, DIC has been of particular interest as it represents one of the most frequent consequences of coronavirus disease 2019 (COVID-19) [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Ultramicronized Palmitoylethanolamide in the Management of Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation

D’Amico

Monaco

Siracusa

et al. 2021

IJMS

View full text Add to dashboard Cite

Disseminated intravascular coagulation (DIC) is a severe condition characterized by the systemic formation of microthrombi complicated with bleeding tendency and organ dysfunction. In the last years, it represents one of the most frequent consequences of coronavirus disease 2019 (COVID-19). The pathogenesis of DIC is complex, with cross-talk between the coagulant and inflammatory pathways. The objective of this study is to investigate the anti-inflammatory action of ultramicronized palmitoylethanolamide (um-PEA) in a lipopolysaccharide (LPS)-induced DIC model in rats. Experimental DIC was induced by continual infusion of LPS (30 mg/kg) for 4 h through the tail vein. Um-PEA (30 mg/kg) was given orally 30 min before and 1 h after the start of intravenous infusion of LPS. Results showed that um-PEA reduced alteration of coagulation markers, as well as proinflammatory cytokine release in plasma and lung samples, induced by LPS infusion. Furthermore, um-PEA also has the effect of preventing the formation of fibrin deposition and lung damage. Moreover, um-PEA was able to reduce the number of mast cells (MCs) and the release of its serine proteases, which are also necessary for SARS-CoV-2 infection. These results suggest that um-PEA could be considered as a potential therapeutic approach in the management of DIC and in clinical implications associated to coagulopathy and lung dysfunction, such as COVID-19.

show abstract

Section: Methodsmentioning

confidence: 99%